适合移植的多发性骨髓瘤患者维持或观察期间外周残留病的微创评估
在GEM2012MENOS65/GEM2014MAIN试验的138例适合移植的多发性骨髓瘤患者中,维持治疗24个周期后采用二代流式(NGF)和质谱(MS)评估外周残留病(PRD)。NGF检测PRD阳性16/138(11.5%)与进展和/或死亡风险增加13倍相关,中位无进展生存期(PFS)和总生存期(OS)分别为2.5和47个月。以骨髓MRD为参照,NGF检测PRD的阳性和阴性预测值分别为100%和73%。NGF和MS均检测不到PRD的患者2年PFS和OS率分别为97%和100%。
要点
- NGF检测PRD阳性16/138(11.5%)与进展和/或死亡风险增加13倍相关。
- PRD阳性患者中位PFS和OS分别为2.5和47个月。
- NGF检测PRD的阳性和阴性预测值分别为100%和73%。
核心结论
- 本研究支持在适合移植的多发性骨髓瘤患者维持或观察期间使用微创PRD监测。
研究设计与样本
- 研究纳入GEM2012MENOS65/GEM2014MAIN临床试验中138例适合移植的多发性骨髓瘤患者,在维持治疗24个周期后评估PRD。
- PRD采用二代流式(NGF)和质谱(MS)评估。
主要发现
- NGF检测PRD阳性16/138(11.5%),与进展和/或死亡风险增加13倍相关。
- PRD阳性患者中位PFS和OS分别为2.5和47个月。
- 以骨髓MRD状态为参照,NGF检测PRD的阳性和阴性预测值分别为100%和73%。
- PRD存在有助于识别骨髓MRD阳性患者中即将进展的风险。
- NGF和MS均检测不到PRD的患者2年PFS和OS率分别为97%和100%。
临床怎么用
- 本研究支持在适合移植的多发性骨髓瘤患者维持或观察期间使用微创PRD监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In multiple myeloma (MM), measurable residual disease (MRD) is assessed in bone marrow (BM). However, less invasive evaluation of peripheral residual disease (PRD) in blood could be advantageous and less cumbersome. We investigated the prognostic value of PRD monitoring after 24 cycles of maintenance in 138 transplant-eligible patients with MM enrolled in the GEM2012MENOS65/GEM2014MAIN clinical trials. PRD was assessed using next-generation flow (NGF) and mass spectrometry (MS). Positive PRD by NGF in 16/138 (11.5%) patients was associated with a 13-fold increased risk of progression and/or death; median progression-free survival (PFS) and overall survival (OS) were 2.5 and 47 months, respectively. Considering patients' MRD status in BM as the reference, PRD detection using NGF showed positive and negative predictive values of 100% and 73%, respectively. Presence of PRD helped identifying patients at risk of imminent progression among those with positive MRD in BM. Patients with undetectable PRD according to both NGF and MS showed 2-year PFS and OS rates of 97% and 100%, respectively. In multivariate analyses including the Revised International Staging System and the complete remission status, only MRD in BM and PRD by NGF showed independent prognostic value for PFS. This study supports the use of less invasive PRD monitoring during maintenance or observation in transplant-eligible patients with MM.
引用
- Lasa M, Notarfranchi L, Agullo C, et al. Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma. J Clin Oncol. 2024. PMID: 39353166. doi:10.1200/JCO.24.00635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。